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Angiogenesis is a critical component of tumor growth. A number of growth factors, including VEGF, FGF, and HGF, have been
implicated as angiogenic growth factors that promote tumor angiogenesis in diﬀerent types of cancer. Ets-1 is the prototypic
member of the Ets transcription factor family. Ets-1 is known to be a downstream mediator of angiogenic growth factors.
Expression of Ets-1 in a variety of diﬀerent tumors is associated with increased angiogenesis. A role for other selected members of
the Ets transcription factor family has also been shown to be important for the development of tumor angiogenesis. Because Ets
factors also express a number of other important genes involved in cell growth, they contribute not only to tumor growth, but to
diseaseprogression.TargetingEtsfactorsinmousetumormodelsthroughtheuseofdominant-negativeEtsproteinsormembrane
permeable peptides directed at competitively inhibiting the DNA binding domain has now demonstrated the therapeutic potential
of inhibiting selected Ets transcription factors to limit tumor growth and disease progression.
Ets-1 is the prototypic member of the Ets transcription
factor family [1] .S e v e r a ls t u d i e sh a v ed e m o n s t r a t e dar o l e
for Ets transcription factors in the regulation of endothelial-
speciﬁc genes including VEGF-R1, VEGF-R2, Tie1, and
Tie2. Whereas, the Ets factors Ets-1 and Ets-2 potently
transactivate the Flt-1 gene promoter, they do not appear
to regulate the Tie1 or Tie2 gene promoters [2, 3]. Ets-1
has been shown to cooperate with HIF-2α in the setting of
hypoxia to regulate the expression of the VEGF-R2 [4, 5].
In contrast, the Ets factor ELF-1 is a potent transactivator
of the Tie1 and Tie2 genes [2, 3]. ELF-1 has been shown
to regulate other genes involved in angiogenesis including
angiopoietin-2 and endothelial nitric oxide synthase [6, 7].
Ets-2 regulates the expression of CD13/aminopeptidase N
(APN) in human endothelial cells [8]. Knockdown of Ets-
2 in human endothelial cells using siRNA oligonucleotides
signiﬁcantly reduced the ability of the endothelial cells to
form tubes and capillary networks. The selectivity of the
diﬀerentEtsfactorstotransactivatediﬀerenttargetgenesalso
correlates with their ability to bind to speciﬁc conserved Ets
binding sites within these genes. However, when the DNA
bindingdomainishighlyhomologous,asisthecaseforEts-1
and Ets-2, there may be a signiﬁcant overlap with respect to
their downstream target genes.
Ets factors can be subcategorized into subfamilies based
on DNA and protein sequence homology. For example,
Elf-1, Nerf-2, and Mef are highly related and belong to
one subfamily. Similarly Fli1 and ERG constitute another
subfamily, as do Ets1 and Ets2. The subfamily members
often have overlapping functions [9]. From an evolutionary
standpoint, this built-in redundancy may be protective
against the eﬀects of genetic mutations of the individual
family members for critical developmental processes such as
vasculogenesis. The DNA binding domain of the Ets family
of proteins is a highly conserved region of approximately 85
residues that shares a strong sequence homology and three-
dimensional structuralscaﬀoldthat closely mimics the helix-
turn-helix family of DNA binding proteins [10, 11]. Previous
investigations have clearly established that the several highly
conserved residues that are localized within the recognition
helix, H3, are responsible for anchoring the Ets domain
through requisite DNA contacts within the major groove.
However,residueswithintheturnsseparatinghelicesH2and
H3 and the ﬁrst two β-strands are also involved in critical
phosphatebackbone contactswithintheDNAminorgroove.
Expressions of selected Ets factors are also enriched at
sites of active blood vessel development during embryo-
genesis. The Ets transcription factor Fli-1 is enriched in2 Journal of Oncology
the developing blood vessels of zebraﬁsh embryos [12]. ELF-
1 is highly expressed in extra-embryonic and embryonic
blood vessels of the developing mouse and chicken embryos
[7,13].TheEtsfactorEts-1isalsoenrichedinthedeveloping
blood vessels of the chicken, and antisense oligonucleotides
have been shown to inhibit angiogenesis when delivered to
the chicken chorioallantoic membrane [14]. Homozygous
inactivation of Ets1 is associated with abnormalities in T cell
function, but with no defects in vascular development or
angiogenesis [15]. Similarly, while Ets2 is a critical regulator
of trophoblast function during extraembryonic development
it is dispensable for development of the embryo proper [16].
Mice with a homozygous hypomorphic mutant of Ets2, in
which the conserved threonine 72 phosphorylation site is
mutated, and Ets2T72A/T72A mice are viable and appear nor-
mal [17]. When both Ets-1 and Ets-2 were simultaneously
targeted, this led to striking defects in vascular development
[18].
In addition to their role in regulating endothelial cell
restricted genes, Ets factors have also been shown to function
upstreamanddownstreamofanumberofangiogenicgrowth
factors [19]. Overexpression of Ets-1 in tissues is associated
with increased expression of both vascular endothelial
growth factor (VEGF) and hepatocyte growth factor (HGF).
Neutralizing antibodies to VEGF and HGF markedly atten-
uate the angiogenic eﬀects of overexpressing Ets-1. Ets-1
regulates the expression of several downstream targets in
endothelial cells that promote an angiogenic phenotype
including the VEGF receptors (VEGF-R1 and VEGF-R2),
urokinase, and several matrix metalloproteinase’s (MMPs)
including MMP-1,MMP-3,MMP-9(Figure 1).Interestingly,
HGF is also capable of inducing the expression of Ets-1,
thereby creating a positive feedback loop at sites where either
Ets-1 or HGF is expressed. In addition to HGF, ﬁbroblast
growthfactor(FGF)andVEGFgeneexpressionareregulated
by Ets-1 [20, 21]. More recently, the chemokine CCL2
(MCP-1/JE) has been shown to promote angiogenesis and
one of the main downstream eﬀectors is Ets-1 [22]. The
particulardownstreamtargetsidentiﬁedinresponsetoCCL2
in endothelial cells are the β3 integrins. Ets-1 is also involved
in the regulation of CCL2 expression [23].
Several studies support a role for Ets-1 expression in the
development of tumor angiogenesis in many diﬀerent types
of human cancer. Increased expression of Ets-1 in tumors
is often associated with a worse prognosis (summarized in
Table 1). In ovarian cancer, for example, Ets-1 expression
strongly correlates with the degree of angiogenesis in the
primary tumor and the development of metastatic lesions
[24]. The prognosis is also signiﬁcantly worse in those
patients with high levels of Ets-1 expression in the tissues
derived from the primary cancer. The survival rate of
patients with histologically demonstrated high levels of Ets-1
expression at 24 months was 30% whereas that of patients
with low levels was 70% [25]. These statistics support the
overall concept that Ets-1 expression in ovarian cancers
contributes to tumor growth and progression that is at least
inpartmediatedbyanincreaseinthedegreeofangiogenesis.
Additional factors promoting tumor growth and progression
are discussed below.
Esophageal squamous cell carcinoma (ESCC) is asso-
ciated with a late presentation due to limited symptoms
early in the disease. However, once detected, ESCC is a
highly aggressive tumor with a propensity to metastasize.
Ets-1 is overexpressed in 44/55 (80%) of tumor tissues
obtained from patients with ESCC [26]. VEGF expression
was observed in most of the Ets-1 overexpressing tissues and
was strongly correlated with lymphnode metastasis. Kaplan-
Meier survival analysis for patients with concomitant tissue
expression of Ets-1 and VEGF demonstrated a signiﬁcantly
worse disease free survival. This again supports the concept
that increased angiogenesis in Ets-1 expressing tumors is
associated with increased tumor progression and a worse
prognosis.
VEGF and Ets-1 are also highly expressed in breast carci-
noma [27]. Ets-1 is expressed in 53% of tumors of patients
with newly diagnosed breast cancer. Ets-1 overexpression in
breast cancer is associated with more invasive tumors and
a signiﬁcantly poorer prognosis [28]. At 5 years, less than
20% of patients with Ets-1 negative tumors have relapsed,
compared to nearly 50% of those with Ets-1 expressing
tumors. The expression of Ets-1 strongly correlated with
the microvessel density within the tumors and lymph node
involvement. In a study of 123 patients with primary breast
cancer followed for 62 months, Ets-1 expression correlated
strongly with VEGF expression and was an independent
predictor of poor prognosis [28]. As a result of these
ﬁndings, antiangiogenic therapy is currently being evaluated
as adjunctive therapy for breast cancer.
In a study of 60 patients with uterine cancer a strong
Ets-1 expression was observed in 66% of patients, and was
associated with increased tumor microvessel density [34].
In patients with cervical carcinoma, high Ets-1 expression
was observed in tissues obtained from 25/60 (42%) patients
and was also associated with a high microvessels density
[30]. Furthermore, the 24-month survival rate of patients
with high ets-1 expression was signiﬁcantly worse at 54%
compared to 92% for those patients with low expression of
Ets-1 in the tumors. These results also support a role for Ets-
1 in tumor progression that is at least in part mediated by
increased angiogenesis.
Ets-1 expression has also been shown to correlate with
higher microvessel density and a worse prognosis in patients
with gastric cancer [31]. Of the 102 patients with primary
gastriccarcinoma,notinvolvinginvasionintothemuscularis
propria or subserosa, Ets-1 expression was observed in 76%
of patients. The 5-year survival rate for these patients was
67% for patients with Ets-1 positive tumors and 89% for
those with Ets-1 negative tumors. Ets-1 expression has also
been evaluated in patients with colorectal carcinoma [32].
High Ets-1 expression was observed in 48.4% of patients
and correlated strongly with increased microvessel density
and the expression of VEGF. Similar to the studies in uterine
cancer, this study also supports a role for expression of Ets-
1 in cancer progression that is at least in part mediated by
increased angiogenesis.
The role of Ets-1 in human brain cancer has also been
evaluated. Ets-1 expression was evaluated in 81 primary and
20 recurrent astrocytic tumors [33]. 65% of glioblastomasJournal of Oncology 3
Table 1: Summary of Ets-1 expression, microvessel density (MVD), and prognosis in human cancer.
Tumor type Number % Ets-1 positive∗ MVD/VEGF Prognosis∗∗
(1) Ovarian [24] 30 66 increased MVD 2 years survival:
10% Ets-1 (+); 60% Ets-1 (−)
(2) Ovarian [25] 30 50 increased MVD 2 years survival:
30% Ets-1 (+); 70% Ets-1 (−)
(3) Esophageal [26] 55 80 increased MVD not evaluated
(4) Breast [27] 48 71 increased MVD not evaluated
(5) Breast [28] 123 62 not evaluated 5 years relapse free survival:
55% Ets-1 (+); 85% Ets-1 (−)
(6) Endometrial [29] 60 66 increased VEGF not evaluated
(7) Cervical [30] 60 42 increased MVD 2 years survival:
54% Ets-1 (+); 92% Ets-1 (−)
(8) Gastric [31] 102 76 increased MVD 5 years survival:
67% Ets-1 (+); 89% Ets-1 (−)
(9) Colon [32] 95 48 increased MVD not evaluated
(10) Brain [33] 101 32 not evaluated not evaluated
“Number” refers to number of patients in the study.
∗% refers to percent of primary tumors that express Ets-1.
∗∗% refers to percent of patients that are relapse free at diﬀerent time points with primary tumors that expressed Ets-1 (+) or did not express Ets-1 (−).
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Figure 1: The role of Ets-1 in tumor development, progression, and angiogenesis. The role of Ets-1 is depicted during diﬀerent stages of
neoplasia from the epithelial-mesenchymal transition (EMT) to tumor growth, invasion, metastasis, and tumor angiogenesis. (∗)d e n o t e s
those genes that are regulated by Ets-1.
(grade IV astrocytomas) stained for Ets-1, 25% of anaplastic
astrocytomas (Grade III) were positive for Ets-1, and none
of the low-grade astrocytomas (Grade II) stained positively
for Ets-1. Therefore the expression of Ets-1 was signiﬁcantly
associated with the tumor grade. Normal brain tissue did
not express signiﬁcant amounts of Ets-1 protein. Ets-1 also
appears to play a role in regulating tumor angiogenesis
in neuroblastomas [35]. Ets-1 expression is higher in
undiﬀerentiated human neuroblastomas. Ets-1 expression is
stimulated by gastrin-releasing peptide (Grp) that stimulates
neuroblastoma growth, and the induction of Ets-1 in these
cells promotes the expression and secretion of the angiogenic
chemokine interleukin-8.
The expressions of Ets factors have also been shown to
be up-regulated in a number of hematological malignancies
either through translocations or through overexpression.
One example of an Ets factor that is involved in several
diﬀerent types of hematological malignancies is Tel (ETV6).4 Journal of Oncology
The hematological malignancies include chronic myeloid
leukemia, acute myeloid leukemia, acute lymphoblastic
leukemia, and non-Hodgkin’s lymphoma [36, 37]. The
evidence that angiogenesis plays a pathophysiological role in
leukemia has been well documented [38]. Angiogenesis in
human leukemias is demonstrated by increased microvessel
density (MVD) in the bone marrow, and is associated with
theincreasedexpressionofhypoxiainduciblefactor1α(HIF-
1α), the increased expression of multiple angiogenic factors
including VEGF, bFGF, and angiopoetin-2, and a reduction
intheexpressionofendogenousangiogenesisinhibitorssuch
as thrombospondin-1 [39]. Because ETV6 has been shown
to be important for yolk sac angiogenesis, its upregulation in
several hematological malignancies also suggests that it may
likely play an important role in regulating angiogenic factors
inhematologicalmalignancies.Furthermore,becauseseveral
oftheEtsfactorshavebeenshowntofunctionasdownstream
eﬀectors of angiogenic factors, targeting ETV6 and other Ets
factors in these cancers may not only limit direct tumor
cell growth but also may limit the local microenvironment
through inhibitory eﬀects on angiogenesis.
With regard to tumor progression, a number of factors
have been shown to promote tumor growth and/or pro-
gression. Some of these are directly regulated by Ets factors,
while others act synergistically with Ets to regulate speciﬁc
target genes. One of the earliest events in the development
of tumors from epithelial cells is the so-called epithelial
to mesenchymal transition (EMT). This process has been
associated with increased expression of RhoC, loss of E-
cadherin, and acquisition of mesenchymal characteristics.
It has recently been shown that the expression of RhoC is
regulated by Ets-1 [40]. The tumor stroma is believed to be
an important contributor to some of the most malignant
characteristics of epithelial tumors. It has recently been
shown that targeted deletion of the tumor suppressor PTEN
in stromal ﬁbroblasts of mouse mammary glands accelerates
the initiation, progression, and malignant transformation
of mammary epithelial tumors [41]. More importantly, it
was found that loss of PTEN in the stromal ﬁbroblasts was
associated with an increase in the expression of Ets-2. The
deletion of Ets-2 and PTEN was associated with a decrease
in tumor vasculature and the recruitment of macrophages,
resulting in fewer and smaller tumors than deleting PTEN
alone. There are other recently described links to certain Ets
proteins and the development of tumor angiogenesis. For
example, the Wilm’s tumor suppressor WT-1 was detected
intheendotheliumofangiogenicbloodvesselsof95%of113
tumorsofdiﬀerentorigins.Ets-1andWT-1haveoverlapping
expression patterns. It was shown that silencing of WT-1 in
endothelial cells reduced cell proliferation, cell migration,
and endothelial tube formation and that silencing of WT-
1 diminished the expression of Ets-1 in the tumors [42].
Mutations of the tumor suppressor gene von Hippel-Lindau
(VHL) are associated with highly vascularized tumors that
in part have been linked to stabilization of the transcription
factor hypoxia-inducible factor (HIF), which upregulates
proangiogenic factors such as vascular endothelial growth
factor (VEGF). Down regulation of VHL in endothelial cells
has recently been linked to Ets-1 activation via increased
FGF signal transduction [43]. In Kaposi’s sarcoma angio-
genesis is associated with the induction of angiopoeitin-2
the expression of which is regulated by the transcription
factors AP-1 and Ets-1 [44]. Another important gene for
the regulation of tumor angiogenesis, wound healing, and
ﬁbrosis is connective tissue growth factor (CCN2). Under
pathological conditions, such as wound healing or tumor
formationithasrecentlybeenshownthatEts-1competitively
inhibits the function of another Ets factor Fli-1 to promote
the expression of CCN2, thereby promoting extracellular
matrix deposition during cancer [45].
From a therapeutic standpoint, recent studies support
important role for Ets factors as critical transcriptional
regulators of tumor angiogenesis. Local administration of
a dominant-negative form of Ets-1, encoding the DNA
binding domain, signiﬁcantly blocked tumor angiogenesis
and tumor growth [46]. Similarly, in a pancreatic mouse
cancer model of angiogenesis, the local administration of
a dominant negative Ets-1 peptide using and adenoviral
vector signiﬁcantly blunted tumor growth and blood vessel
density [47]. By targeting the DNA binding domain, these
therapeuticagentsverylikelytargetsubfamiliesofEtsfactors,
for example, Ets-1 and Ets-2, rather than being entirely
selective for a particular Ets factor [7].
Administration of dominant negative Ets proteins has
not been successfully used to block tumor growth system-
ically. Another strategy that has been used to inhibit the
function of transcription factors is the use of membrane
permeable peptides. For example, a peptide with a mem-
branepermeablesequenceandthenuclearlocalizationsignal
sequenceof the transcription factorNF-κB canblocknuclear
import of this transcription factor upon activation [48]. The
inhibitory function of this peptide, however, was not speciﬁc
to NF-κB, and also inhibited other transcription factors such
as AP-1, NFAT, and STAT1 from entering the nucleus [49].
Another membrane permeable peptide with the ability to
interfere with DNA binding of a transcription factor was
recently demonstrated using the Tet repressor (TetR) of
Escherichia coli synthesized in tandem with a cell membrane
transducing peptide. This peptide was able to repress the
expression of a tetracycline responsive reporter unit stably
transfected into the genome of HeLa cells [50]. Membrane
permeable peptides consisting of the terminal portion of the
DNA binding domain of the Ets factor Elf-1 in tandem with
the HIV TAT peptide readily cross the cell membrane and
enter the nucleus of cells where they are able to block the
function of the Ets factor Elf-1. These peptides were success-
fully used to systemically block the growth of B16 melanoma
tumor cells in vivo [7]. Furthermore, the identiﬁcation of
relativelyshortpeptidesof30to40aminoacidslongthatcan
selectively block the DNA binding of speciﬁc transcription
factors, or subsets of transcription factors, suggests that
this may be a very potent novel approach toward targeting
transcription factors as a therapeutic modality to inhibit
tumor growth and angiogenesis. Although these peptides
have been used successfully to block tumor growth in small
animals, there may be certain limitations. First the cost
of making these peptides may be prohibitive for use on
a much larger scale in man. Second, if the peptides areJournal of Oncology 5
to be used repeatedly, the peptides may be immunogenic
and antibodies directed against the peptides may eventually
limit their use. With recent advances in drug discovery,
the identiﬁcation and/or development of small molecule
inhibitors of subfamilies of Ets factors may be possible
in the future by taking advantage of structural similarities
among the subfamilies in the DNA binding domain or other
functionally conserved regions of the proteins. Although
transcriptionfactorshavehistoricallybeenpoordrugtargets,
theadvancesincomputationalchemistrymayultimatelylead
to the identiﬁcation of selective inhibitors of Ets and other
transcription factors.
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